KR101319630B1 - 퓨린 화합물 - Google Patents

퓨린 화합물 Download PDF

Info

Publication number
KR101319630B1
KR101319630B1 KR1020117014000A KR20117014000A KR101319630B1 KR 101319630 B1 KR101319630 B1 KR 101319630B1 KR 1020117014000 A KR1020117014000 A KR 1020117014000A KR 20117014000 A KR20117014000 A KR 20117014000A KR 101319630 B1 KR101319630 B1 KR 101319630B1
Authority
KR
South Korea
Prior art keywords
methyl
tetrahydro
purine
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117014000A
Other languages
English (en)
Korean (ko)
Other versions
KR20110084459A (ko
Inventor
피터 찰스 애스틀레스
로셀라 귀데티
션 패트릭 홀린스헤드
마이클 웨이드 티드웰
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110084459A publication Critical patent/KR20110084459A/ko
Application granted granted Critical
Publication of KR101319630B1 publication Critical patent/KR101319630B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020117014000A 2008-12-18 2009-12-09 퓨린 화합물 Expired - Fee Related KR101319630B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
US61/138,589 2008-12-18
PCT/US2009/067249 WO2010080306A1 (en) 2008-12-18 2009-12-09 Purine compounds

Publications (2)

Publication Number Publication Date
KR20110084459A KR20110084459A (ko) 2011-07-22
KR101319630B1 true KR101319630B1 (ko) 2013-10-17

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117014000A Expired - Fee Related KR101319630B1 (ko) 2008-12-18 2009-12-09 퓨린 화합물

Country Status (29)

Country Link
US (1) US8252798B2 (https=)
EP (1) EP2379555B1 (https=)
JP (1) JP5559812B2 (https=)
KR (1) KR101319630B1 (https=)
CN (1) CN102256977B (https=)
AR (1) AR075104A1 (https=)
AU (1) AU2009335997B2 (https=)
BR (1) BRPI0923195A2 (https=)
CA (1) CA2746740C (https=)
CL (1) CL2011001464A1 (https=)
CO (1) CO6390101A2 (https=)
CR (1) CR20110340A (https=)
DO (1) DOP2011000196A (https=)
EA (1) EA018386B1 (https=)
EC (1) ECSP11011151A (https=)
ES (1) ES2536880T3 (https=)
HN (1) HN2011001700A (https=)
IL (1) IL213167A (https=)
MA (1) MA32904B1 (https=)
MX (1) MX2011006442A (https=)
NZ (1) NZ593088A (https=)
PA (1) PA8851501A1 (https=)
PE (1) PE20110999A1 (https=)
SG (1) SG172253A1 (https=)
TN (1) TN2011000291A1 (https=)
TW (1) TWI376378B (https=)
UA (1) UA104010C2 (https=)
WO (1) WO2010080306A1 (https=)
ZA (1) ZA201103943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
IN2012DN02474A (https=) 2009-08-28 2015-08-21 Arena Pharm Inc
US20130096104A1 (en) * 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
BR112012024587A2 (pt) * 2010-03-31 2016-05-31 Lilly Co Eli compostos de purina usados como agonistas de cb2
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
BR112013011520A2 (pt) 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
CN103827115A (zh) * 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
CN104903316B (zh) * 2012-08-16 2017-11-28 詹森药业有限公司 作为n型钙通道阻滞剂的取代的吡唑
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
HUE035333T2 (en) * 2013-05-02 2018-05-02 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037823A1 (en) * 2002-10-28 2004-05-06 Pfizer Products Inc. Purine compounds and uses thereof as cannabinoid receptor ligands

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20070054737A (ko) * 2004-10-22 2007-05-29 화이자 프로덕츠 인코포레이티드 퓨린 화합물의 제조 방법
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
KR101450535B1 (ko) * 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
US20120295915A1 (en) * 2009-11-24 2012-11-22 Chaudhari Amita M Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037823A1 (en) * 2002-10-28 2004-05-06 Pfizer Products Inc. Purine compounds and uses thereof as cannabinoid receptor ligands

Also Published As

Publication number Publication date
SG172253A1 (en) 2011-07-28
DOP2011000196A (es) 2011-10-31
IL213167A (en) 2013-11-28
PE20110999A1 (es) 2012-01-16
TN2011000291A1 (en) 2012-12-17
ZA201103943B (en) 2012-11-28
CN102256977B (zh) 2014-04-16
CO6390101A2 (es) 2012-02-29
KR20110084459A (ko) 2011-07-22
ECSP11011151A (es) 2011-07-29
CA2746740A1 (en) 2010-07-15
JP2012512873A (ja) 2012-06-07
ES2536880T3 (es) 2015-05-29
CN102256977A (zh) 2011-11-23
CR20110340A (es) 2011-09-16
AU2009335997A1 (en) 2011-06-23
MX2011006442A (es) 2011-07-19
US8252798B2 (en) 2012-08-28
EA201170832A1 (ru) 2011-12-30
HN2011001700A (es) 2013-05-06
CL2011001464A1 (es) 2012-01-20
EP2379555A1 (en) 2011-10-26
JP5559812B2 (ja) 2014-07-23
PA8851501A1 (es) 2010-07-27
WO2010080306A1 (en) 2010-07-15
IL213167A0 (en) 2011-07-31
BRPI0923195A2 (pt) 2016-02-16
EP2379555B1 (en) 2015-02-25
NZ593088A (en) 2012-12-21
AU2009335997B2 (en) 2012-05-10
AR075104A1 (es) 2011-03-09
EA018386B1 (ru) 2013-07-30
MA32904B1 (fr) 2011-12-01
TWI376378B (en) 2012-11-11
UA104010C2 (en) 2013-12-25
US20100160288A1 (en) 2010-06-24
TW201024296A (en) 2010-07-01
CA2746740C (en) 2014-01-14

Similar Documents

Publication Publication Date Title
KR101319630B1 (ko) 퓨린 화합물
EP2552909B1 (en) 4-aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
JPH09504520A (ja) １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
EP2552921B1 (en) Purine compounds
AU2011235290B2 (en) Purine compounds used as CB2 agonists
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181012

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181012